New opportunities in Europe for generics and biosimilar companies

Ulla Klinge reports. An SPC (Supplementary Protection Certificate) is a right issued on the basis of a patent and a marketing authorisation for a drug,and which extends the period of protection for the patented drug for up to 5 years. Until now the holder of an SPC has been able to prohibit any other company ...

read more